Multivariate survival analysis for event-free survival
| Prognostic factor . | Coefficient . | SE . | P . | Hazard ratio . |
|---|---|---|---|---|
| B symptoms pre-ICE (baseline = no) | 0.519 | 0.208 | .012 | 1.680 |
| Ref/rel < 1 y vs > 1 y (baseline < 1 y) | −0.533 | 0.237 | .025 | 0.587 |
| Extranodal disease (baseline = no) | 0.626 | 0.242 | .009 | 1.870 |
| Prognostic factor . | Coefficient . | SE . | P . | Hazard ratio . |
|---|---|---|---|---|
| B symptoms pre-ICE (baseline = no) | 0.519 | 0.208 | .012 | 1.680 |
| Ref/rel < 1 y vs > 1 y (baseline < 1 y) | −0.533 | 0.237 | .025 | 0.587 |
| Extranodal disease (baseline = no) | 0.626 | 0.242 | .009 | 1.870 |
Patients with B symptoms have a 1.68-fold risk for treatment failure compared to patients without B symptoms. The 95% CI is (1.118, 2.526). Patients who have had a complete remission lasting more than 1 year have a 0.587-fold risk for treatment failure compared to patients who have had a remission duration less than 1 year and those with primary refractory disease. The 95% CI is (0.369, 0.934). Patients with extranodal disease have a 1.87-fold risk for treatment failure compared to patients without extranodal disease. The 95% CI is (1.164, 3.005).
SE indicates standard error; for other abbreviations, see Table 2.